Qiagen N.V. (QGEN) est une société cotée en bourse dans le Santé secteur, opérant dans le Medical - Diagnostics & Research secteur d'activité. Le siège social de l'entreprise est situé à Venlo, Netherlands. Le PDG actuel est Roland Sackers.
QGEN a date d'introduction en bourse 1996-06-28, 5,700 employés à temps plein, cotée sur le NYSE, une capitalisation boursière de $8.61B.
QIAGEN N.V. is a global provider of sample-to-insight solutions that convert biological materials into molecular insights for diagnostic, research, and applied testing applications. The company offers a comprehensive portfolio of consumables, instruments, and bioinformatics services spanning primary and secondary sample processing, nucleic acid purification, PCR analysis, next-generation sequencing, and molecular diagnostics across oncology, infectious disease, and human identification. QIAGEN serves molecular diagnostics laboratories, academic institutions, pharmaceutical companies, and applied testing customers worldwide through its proprietary silica membrane and magnetic bead technologies, as well as integrated platforms for automated molecular analysis. The company maintains strategic partnerships with leading healthcare and biotechnology firms to expand its capabilities and market reach.
